Free Trial
→ Your Bank Account Is No Longer Safe (From Priority Gold) (Ad)tc pixel

Zhengye Biotechnology (NASDAQ:ZYBT) Stock Price Up 19.8% - Still a Buy?

Written by MarketBeat
Updated September 6, 2025
Zhengye Biotechnology logo with Medical background

Key Points

  • Zhengye Biotechnology's stock price surged by 19.8%, reaching a high of $11.37 before settling at $11.21 on the latest trading day.
  • Analyst ratings for the company have been adjusted, with Wall Street Zen upgrading the stock to a "hold" rating.
  • Several institutional investors, including Geode Capital Management and Invesco Ltd., have recently acquired new stakes in Zhengye Biotechnology during the second quarter.
  • Five stocks we like better than Zhengye Biotechnology.

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT - Get Free Report)'s stock price traded up 19.8% during trading on Tuesday . The stock traded as high as $11.37 and last traded at $11.21. 106,820 shares changed hands during trading, a decline of 65% from the average session volume of 305,725 shares. The stock had previously closed at $9.36.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Zhengye Biotechnology to a "hold" rating in a report on Saturday, August 2nd.

Get Our Latest Stock Report on Zhengye Biotechnology

Zhengye Biotechnology Trading Up 4.1%

The company has a current ratio of 1.31, a quick ratio of 0.88 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $6.77 and a 200 day simple moving average of $6.91.

Hedge Funds Weigh In On Zhengye Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of Zhengye Biotechnology in the second quarter worth about $1,158,000. Invesco Ltd. acquired a new position in Zhengye Biotechnology in the 2nd quarter worth approximately $220,000. Finally, Geode Capital Management LLC purchased a new position in Zhengye Biotechnology during the 2nd quarter worth approximately $174,000.

About Zhengye Biotechnology

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

See Also

Should You Invest $1,000 in Zhengye Biotechnology Right Now?

Before you consider Zhengye Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zhengye Biotechnology wasn't on the list.

While Zhengye Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover
Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.